<< Netherlands shows the way in healthcare accountability | TAHU recommends revision of proposed healthcare plan >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Validity of Unigene’s patent on Fortical confirmed by the court

Published on September 3, 2009 at 5:41 AM · No Comments

Unigene Laboratories, Inc. (OTCBB: UGNE) has reported that the U.S. District Court, Southern District of New York, has confirmed the validity of Unigene’s patent on Fortical® and issued an order permanently enjoining Apotex Inc. and Apotex Corp. from further infringement of the patent. The motion of the plaintiffs, Unigene and its licensee Upsher-Smith Laboratories, for summary judgment in the case was granted while the request for summary judgment by Apotex was denied.

“This decision is a very significant development for the plaintiffs,” commented Dr. Warren P. Levy, President and CEO of Unigene. “Although this decision may not close all of the legal proceedings, we are encouraged by the court’s decision in our favor.”

http://www.unigene.com

Posted in: Medical Patent News

Tags: , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading